Drug intelligence / Profile preview

LL-E7P-IL-12D

Development stage: Preclinical
Lead developer: Xinjiang University
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intranasal

Overview

**LL-E7P-IL-12D** is a preclinical intranasal therapeutic cancer-vaccine candidate consisting of a live, cell-wall-weakened recombinant *Lactococcus lactis* strain engineered to express human papillomavirus type 16 E7 protein and to deliver a eukaryotic expression cassette encoding murine interleukin-12. It was designed to generate HPV-16 E7-specific cytotoxic T-cell responses while locally increasing IL-12-driven immune activation. In C57BL/6 mice bearing HPV-16 E7-expressing TC-1 tumors, intranasal administration induced E7-specific cytotoxic lymphocyte activity, increased serum IL-12 and interferon-gamma, inhibited tumor growth, and produced tumor-free animals in prophylactic and therapeutic experiments. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3881950/))

Targets

HPV16 E7 (Human papillomavirus 16 E7 protein)

Beyond the preview

Go deeper on LL-E7P-IL-12D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LL-E7P-IL-12D.

Explore the full profile